Nm. Lindor et al., Papillary renal cell carcinoma: Analysis of germline mutations in the MET proto-oncogene in a clinic-based population, GENET TEST, 5(2), 2001, pp. 101-106
Approximately 10% of all renal cell carcinomas (RCCs) present a distinctive
papillary histology. Familial papillary RCC (PRCC) has been described, but
the majority of cases appear to be sporadic. Recently, germline mutations
in the MET proto-oncogene on chromosome 7 have been identified in families
with hereditary PRCC. We evaluated 59 patients with PRCC for the frequency
of MET germline mutations to determine the value of genetic screening of th
is patient population. Between 1976 and 1997, 165 patients were identified
with PRCC by retrospective chart review. Fifty-nine of 133 surviving patien
ts agreed to provide a family history, a blood specimen, and informed conse
nt for genetic research. DNA was isolated from peripheral blood leukocytes.
Denaturing high-performance liquid chromatography (DHPLC) followed by geno
mic sequencing was performed on eight exons of the MET proto-oncogene, incl
uding exons 5-7 of the extracellular domain, exon 14, and exons 16-19 of th
e tyrosine kinase domain. The 59 patients in this study included 49 men and
10 women with a mean age at diagnosis of 61 years. Bilateral and/or multif
ocal disease was present in 13 cases (22%). No germline mutations were dete
cted in the studied exons of the MET proto-oncogene (exons previously repor
ted to contain deleterious mutations in familial PRCC). No pathological MET
proto-oncogene germline mutations were identified in 59 patients with PRCC
. The germline mutation rate in this clinic-based population of individuals
with PRCC approaches 0% (CI = 0-6.18). MET proto-oncogene germline mutatio
n screening does not appear to be clinically indicated in patients with PRC
C without additional evidence for a genetic predisposition (positive family
history, unusual age at onset, bilateral disease).